Stock MIRA MIRA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials MIRA Pharmaceuticals, Inc.

Equities

MIRA

US60458C1045

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 11:47:13 2024-07-09 am EDT 		5-day change 1st Jan Change
0.5403 USD -1.37% Intraday chart for MIRA Pharmaceuticals, Inc. -10.35% -48.54%
Jun. 24 MIRA Pharmaceuticals, Inc. Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing CI
Jun. 10 MIRA Pharmaceuticals, Inc. Announces Positive Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year CI

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 15.52 8.097 - -
Enterprise Value (EV) 1 15.52 8.097 8.097 8.097
P/E ratio -1.64 x -1.57 x -1.48 x -
Yield - - - -
Capitalization / Revenue - - - 0.01 x
EV / Revenue - - - 0.01 x
EV / EBITDA - -1.64 x -1.69 x 0.01 x
EV / FCF - 46.4 x -0.79 x 0.02 x
FCF Yield - 2.16% -127% 4,918%
Price to Book - - - -
Nbr of stocks (in thousands) 14,781 14,781 - -
Reference price 2 1.050 0.5478 0.5478 0.5478
Announcement Date 4/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - - - - 552
EBITDA 1 - - -4.947 -4.799 546.6
EBIT 1 - - -4.965 -4.82 546.6
Operating Margin - - - - 99.01%
Earnings before Tax (EBT) -7.058 - - - -
Net income -7.058 -11.98 - -8.559 -
Net margin - - - - -
EPS 2 - -0.6400 -0.3500 -0.3700 -
Free Cash Flow 1 - - 0.1746 -10.3 398.2
FCF margin - - - - 72.13%
FCF Conversion (EBITDA) - - - - 72.85%
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 6/29/23 4/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2 2023 Q3 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - - -
EBITDA - - - - - - - -
EBIT - - - - - - - -
Operating Margin - - - - - - - -
Earnings before Tax (EBT) - - - - - - - -
Net income 1 - - - -1.849 -2.938 -3.086 - -
Net margin - - - - - - - -
EPS 2 - - - -0.0800 -0.0900 -0.1200 -0.0900 -0.0800
Dividend per Share - - - - - - - -
Announcement Date 9/15/23 11/13/23 5/13/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - - 0.17 -10.3 398
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 6/29/23 4/1/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MIRA PHARMACEUTICALS, INC. Stock MIRA Pharmaceuticals, Inc.
-48.54% 8.1M
MODERNA, INC. Stock Moderna, Inc.
+16.91% 44.63B
LONZA GROUP AG Stock Lonza Group AG
+42.66% 40.46B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.76% 38.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+33.55% 32.27B
CELLTRION, INC. Stock Celltrion, Inc.
-7.10% 27.3B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.45% 26.53B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+47.11% 14.06B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.89% 12.54B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-8.07% 11.28B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MIRA Stock
  4. Financials MIRA Pharmaceuticals, Inc.